Berlin, Germany

Alfred Seewald

This inventor holds 1 USPTO granted patent. Top assignee: Basf Aktiengesellschaft. Active years: 1978.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 1978

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Alfred Seewald: Innovator in Chemical Compounds

Introduction

Alfred Seewald is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of chemistry, particularly in the development of cyclic esters. His work has implications for various chemical applications, showcasing his innovative spirit and expertise.

Latest Patents

Alfred Seewald holds a patent for "Cyclic esters of 3,4-dihydroxy-thiophene-1,1-dioxide compounds and cyclic esters of 3,4-dihydroxy-thiophene-1,1-dioxide and of the corresponding cyclopentadienone compound, and their manufacture." This patent highlights the potential use of these compounds as 'solid forms' of phosgene, thiophosgene, or oxalyl chloride, as well as acyl transfer agents. He has 1 patent to his name, reflecting his focused contributions to the field.

Career Highlights

Alfred Seewald is associated with BASF Aktiengesellschaft, a leading chemical company known for its innovative solutions. His role at BASF has allowed him to explore and develop new chemical compounds that can have a significant impact on various industries.

Collaborations

Throughout his career, Alfred has collaborated with esteemed colleagues such as Wolfgang Steglich and Oswald Hollitzer. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Alfred Seewald's work in the field of chemical compounds exemplifies the spirit of innovation. His contributions, particularly in the area of cyclic esters, demonstrate the importance of research and development in advancing chemical applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…